**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Michel Chedid El Helou, Cleveland Clinic, Cleveland, Ohio

**Main Body of the Abstract**
Purpose
To review our center’s experience with heart transplant in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
Methods
We retrospectively analyzed all patients who underwent heart transplant at the Cleveland Clinic for heart failure due to ATTR-CM. Patient demographics, clinical characteristics, hospitalizations, and survival data were extracted.
Result
The cohort comprised a total of 32 patients. Median age at diagnosis was 65 and median age at transplantation was 67 years. Eight patients had wild-type (wtATTR) and 24 had hereditary ATTR-CM (hATTR), with Val122Ile being the predominant variant (19 patients). Five patients (4 hATTR and one wtATTR) had a heart-kidney transplant and 2 (hATTR) had a heart-liver transplant. Post-transplant, 16 patients were treated with Tafamidis, and 3 hATTR patients with gene silencers. Median follow-up was 3.3 years with 25 of 32 patients alive at time of data extraction. Estimated survival rates were 97% and 84% at 1 and 3 years respectively. Causes of death (7 patients) included COVID, sudden death, acute liver rejection, infection, graft dysfunction, and renal failure. No patients had recurring amyloid in the allograft. One patient with Val122Ile followed up for 15 years developed autonomic and peripheral neuropathy, and one with Thr60Ala developed severe autonomic neuropathy.
Conclusions
Heart transplant for patients with ATTR-CM in our center showed promising outcomes, suggesting it as a viable therapeutic option for select patients. Longer-term analyses are warranted to confirm these findings and refine patient selection and post-transplant management strategies.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Michel Chedid El Helou, Cleveland Clinic, Cleveland, Ohio

**Main Body of the Abstract**
**Purpose**
To review our center’s experience with heart transplant in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
**Methods**
We retrospectively analyzed all patients who underwent heart transplant at the Cleveland Clinic for heart failure due to ATTR-CM. Patient demographics, clinical characteristics, hospitalizations, and survival data were extracted.
**Result**
The cohort comprised a total of 32 patients. Median age at diagnosis was 65 and median age at transplantation was 67 years. Eight patients had wild-type (wtATTR) and 24 had hereditary ATTR-CM (hATTR), with Val122Ile being the predominant variant (19 patients). Five patients (4 hATTR and one wtATTR) had a heart-kidney transplant and 2 (hATTR) had a heart-liver transplant. Post-transplant, 16 patients were treated with Tafamidis, and 3 hATTR patients with gene silencers. Median follow-up was 3.3 years with 25 of 32 patients alive at time of data extraction. Estimated survival rates were 97% and 84% at 1 and 3 years respectively. Causes of death (7 patients) included COVID, sudden death, acute liver rejection, infection, graft dysfunction, and renal failure. No patients had recurring amyloid in the allograft. One patient with Val122Ile followed up for 15 years developed autonomic and peripheral neuropathy, and one with Thr60Ala developed severe autonomic neuropathy.
**Conclusions**
Heart transplant for patients with ATTR-CM in our center showed promising outcomes, suggesting it as a viable therapeutic option for select patients. Longer-term analyses are warranted to confirm these findings and refine patient selection and post-transplant management strategies.



Heart Transplant in Transthyretin Cardiac Amyloidosis: A Single-Center Experience PB148 (#121)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.